BlackRock Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

BlackRock Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.32M	Buy	45,695 +9,259	+25%	+$245K	﹤0.01%	2508
2016 Q3	$1.16M	Buy	36,436 +1,067	+3%	+$36.2K	﹤0.01%	2568
2016 Q2	$1.15M	Sell	35,369 -258,595	-88%	-$8.65M	﹤0.01%	2527
2016 Q1	$8.22M	Buy	293,964 +12,124	+4%	+$264K	0.01%	1045
2015 Q4	$10M	Buy	281,840 +1,515	+0.5%	+$53.4K	0.01%	938
2015 Q3	$9.27M	Sell	280,325 -3,357	-1%	-$140K	0.01%	973
2015 Q2	$11.9M	Buy	283,682 +63,974	+29%	+$2.48M	0.01%	892
2015 Q1	$7.16M	Buy	219,708 +2,985	+1%	+$103K	0.01%	1152
2014 Q4	$6.88M	Sell	216,723 -1,783	-0.8%	-$50.6K	0.01%	1167
2014 Q3	$5.41M	Sell	218,506 -28,144	-11%	-$658K	0.01%	1285
2014 Q2	$5.57M	Buy	246,650 +30,840	+14%	+$644K	0.01%	1314
2014 Q1	$5.25M	Buy	215,810 +20,727	+11%	+$524K	0.01%	1331
2013 Q4	$4.88M	Sell	195,083 -4,992	-2%	-$118K	0.01%	1367
2013 Q3	$5.5M	Buy	200,075 +11,589	+6%	+$242K	0.01%	1224
2013 Q2	$3.42M	Buy	+188,486	New	+$2.6M	0.01%	1469

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock Investment Management's ACAD Position: Q4 2016 in Review

BlackRock Investment Management increased its Acadia Pharmaceuticals (ACAD) stake by 25% in Q4 2016, buying an estimated $245K and bringing the position to 45,695 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

BlackRock Investment Management first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $11.9M in Q2 2015. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

BlackRock Investment Management held 45,695 shares of Acadia Pharmaceuticals worth $1.32M as of Q4 2016.
BlackRock Investment Management bought 9,259 Acadia Pharmaceuticals shares in Q4 2016, an estimated $245K.
Acadia Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2508 holding.
BlackRock Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Acadia Pharmaceuticals position peaked at $11.9M in Q2 2015.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.